Key Takeaways Amgen shares jumped almost 16% in a month on strong Q3 results and higher sales guidance.Growing demand for key drugs, new products and biosimilars is driving Amgen's revenue gains.Amgen's expanding pipeline, including MariTide, offers multiple upcoming catalysts.Amgen’s (AMGN) stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also raised its sales guidance for the ...